An update from Emergent Biosolutions (EBS) is now available.
Emergent BioSolutions Inc. has successfully completed the sale of its Baltimore-Camden drug product facility to a subsidiary of Bora Pharmaceuticals, securing roughly $30 million at the deal’s closing. This strategic move, subject to standard post-closing adjustments, marks a significant financial event for the company, capturing the interest of stock market enthusiasts.
See more data about EBS stock on TipRanks’ Stock Analysis page.
